Cargando…
Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
Background and Aims: Peripheral neuropathy is a common complication of chemotherapy that can induce marked disability that negatively affects the quality of life in patients with multiple myeloma (MM). The aim of this study was to prevent the onset or the worsening of peripheral neuropathy in MM pat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247541/ https://www.ncbi.nlm.nih.gov/pubmed/30295079 http://dx.doi.org/10.1177/1534735418803758 |
_version_ | 1783372497428676608 |
---|---|
author | Maschio, Marta Zarabla, Alessia Maialetti, Andrea Marchesi, Francesco Giannarelli, Diana Gumenyuk, Svitlana Pisani, Francesco Renzi, Daniela Galiè, Edvina Mengarelli, Andrea |
author_facet | Maschio, Marta Zarabla, Alessia Maialetti, Andrea Marchesi, Francesco Giannarelli, Diana Gumenyuk, Svitlana Pisani, Francesco Renzi, Daniela Galiè, Edvina Mengarelli, Andrea |
author_sort | Maschio, Marta |
collection | PubMed |
description | Background and Aims: Peripheral neuropathy is a common complication of chemotherapy that can induce marked disability that negatively affects the quality of life in patients with multiple myeloma (MM). The aim of this study was to prevent the onset or the worsening of peripheral neuropathy in MM patients treated with bortezomib (BTZ), using a new nutritional neuroprotective compound. We report preliminary results of 18 out of 33 patients who completed the study. Methods: We administered a tablet of Neuronorm to patients, containing docosahexaenoic acid 400 mg, α-lipoic acid 600 mg, vitamin C 60 mg, and vitamin E 10 mg bid for the whole follow-up period. Neurological visit assessment, electroneurography, and evaluation scales were performed at baseline and after 6 months. Results: At 6 months, 8 patients had no chemotherapy-induced peripheral neuropathy, while 10 patients experienced chemotherapy-induced peripheral neuropathy of grade 1 according to the Common Terminology Criteria for Adverse Events, one of them with pain. Seventeen patients did not report painful symptoms; no limitation of functional autonomy and stability in quality of life domains explored was observed. Conclusions: Our results seem to indicate that early introduction of a neuroprotective agent in our patients with MM treated with BTZ could prevent the onset or the worsening of neuropathic pain, avoiding the interruption of the therapy with BTZ, and maintaining a good functional autonomy to allow normal daily activities. Despite the limitations due to the fact that this is a preliminary study, in a small population, with short follow-up, our data seem to indicate that the nutraceutical may have some potential to be considered for a future trial. |
format | Online Article Text |
id | pubmed-6247541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-62475412018-11-26 Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data Maschio, Marta Zarabla, Alessia Maialetti, Andrea Marchesi, Francesco Giannarelli, Diana Gumenyuk, Svitlana Pisani, Francesco Renzi, Daniela Galiè, Edvina Mengarelli, Andrea Integr Cancer Ther Research Articles Background and Aims: Peripheral neuropathy is a common complication of chemotherapy that can induce marked disability that negatively affects the quality of life in patients with multiple myeloma (MM). The aim of this study was to prevent the onset or the worsening of peripheral neuropathy in MM patients treated with bortezomib (BTZ), using a new nutritional neuroprotective compound. We report preliminary results of 18 out of 33 patients who completed the study. Methods: We administered a tablet of Neuronorm to patients, containing docosahexaenoic acid 400 mg, α-lipoic acid 600 mg, vitamin C 60 mg, and vitamin E 10 mg bid for the whole follow-up period. Neurological visit assessment, electroneurography, and evaluation scales were performed at baseline and after 6 months. Results: At 6 months, 8 patients had no chemotherapy-induced peripheral neuropathy, while 10 patients experienced chemotherapy-induced peripheral neuropathy of grade 1 according to the Common Terminology Criteria for Adverse Events, one of them with pain. Seventeen patients did not report painful symptoms; no limitation of functional autonomy and stability in quality of life domains explored was observed. Conclusions: Our results seem to indicate that early introduction of a neuroprotective agent in our patients with MM treated with BTZ could prevent the onset or the worsening of neuropathic pain, avoiding the interruption of the therapy with BTZ, and maintaining a good functional autonomy to allow normal daily activities. Despite the limitations due to the fact that this is a preliminary study, in a small population, with short follow-up, our data seem to indicate that the nutraceutical may have some potential to be considered for a future trial. SAGE Publications 2018-10-08 /pmc/articles/PMC6247541/ /pubmed/30295079 http://dx.doi.org/10.1177/1534735418803758 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Articles Maschio, Marta Zarabla, Alessia Maialetti, Andrea Marchesi, Francesco Giannarelli, Diana Gumenyuk, Svitlana Pisani, Francesco Renzi, Daniela Galiè, Edvina Mengarelli, Andrea Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data |
title | Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data |
title_full | Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data |
title_fullStr | Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data |
title_full_unstemmed | Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data |
title_short | Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data |
title_sort | prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and α-lipoic acid in patients with multiple myeloma: preliminary data |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247541/ https://www.ncbi.nlm.nih.gov/pubmed/30295079 http://dx.doi.org/10.1177/1534735418803758 |
work_keys_str_mv | AT maschiomarta preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT zarablaalessia preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT maialettiandrea preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT marchesifrancesco preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT giannarellidiana preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT gumenyuksvitlana preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT pisanifrancesco preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT renzidaniela preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT galieedvina preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata AT mengarelliandrea preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata |